🇺🇸 FDA
Pipeline program

Anti-PD1

IRB NO. 202400085B0

Unknown small_molecule completed

Quick answer

Anti-PD1 for Nasopharyngeal Carcinoma (NPC) is a Unknown program (small_molecule) at Hospital Authority, Hong Kong with 1 ClinicalTrials.gov record(s).

Program details

Company
Hospital Authority, Hong Kong
Indication
Nasopharyngeal Carcinoma (NPC)
Phase
Unknown
Modality
small_molecule
Status
completed

Clinical trials